Rapamycin can Inhibit the Development of Chlamydia pneumoniae, which Might Partly Contribute to the Prevention of In-stent Restenosis

Y Yan, S Silvennoinen-Kassinen, M Leinonen… - … drugs and therapy, 2010 - Springer
Background Rapamycin, an immunosuppressive and antiproliferative drug, is used to
prevent neointima formation to reduce the risk of in-stent restenosis with rapamycin eluting …

Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double …

FJ Neumann, A Kastrati, T Miethke, G Pogatsa-Murray… - The Lancet, 2001 - thelancet.com
Summary Background Vascular infection with Chlamydia pneumoniae might boost
inflammatory responses that play a pivotal part in neointima formation, which is the main …

Chlamydia pneumoniae Infection and Restenosis in Patients with Coronary Heart Disease

R Krausse, J Leiendecker, G Herrmann, T Harder… - Infection, 2003 - Springer
Background: The aim of this study was to establish whether Chlamydia pneumoniae is
implicated in the development of restenosis in patients with coronary heart disease (CHD) …

Chlamydia pneumoniae seropositivity predicts the risk of restenosis after percutaneous transluminal coronary angioplasty

K Hayashida, M Tanaka, H Morita, F Hayashi, T Inada… - Heart and Vessels, 2002 - Springer
This study was done to evaluate whether anti-Chlamydia pneumoniae seropositivity can be
a predictor of restenosis after coronary intervention. Recent studies indicate that latent …

Preventing restenosis after implantation of bare stents with oral rapamycin: a randomized angiographic and intravascular ultrasound study with a 5-year clinical follow …

C Cernigliaro, M Sansa, G Vitrella, A Verde, AS Bongo… - Cardiology, 2009 - karger.com
Objectives: To establish the efficacy of oral rapamycin at a dose of 2 mg for 1 month at
reducing the 6-month restenosis rate after the implantation of bare metal stents. Methods: A …

Oral rapamycin to prevent human coronary stent restenosis: a pilot study

E Guarda, E Marchant, A Fajuri, A Martínez… - American Heart …, 2004 - Elsevier
BACKGROUND: Recent human trials with rapamycin-eluting stents have shown very low
restenosis rates. However, the high costs of these devices preclude their use in routine …

A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody …

J Kaehler, A Haar, KP Schaps, A Gaede… - American Heart …, 2005 - Elsevier
BACKGROUND: Elevated antibodies against Chlamydia pneumoniae have been
associated with coronary artery disease. In patients undergoing percutaneous coronary …

[PDF][PDF] Effect of Chlamydia pneumoniae infection on coronary flow reserve and intimal hyperplasia after stent implantation in patients with angina pectoris

T Tanaka, M Matsushita, Y Oka, T Sada… - Journal of …, 2001 - jcc-web.sakura.ne.jp
Objectives. Chlamydia pneumoniae (C. pneumoniae) has been detected in tissue from
coronary atherosclerotic vascular lesions and may be involved in the pathogenesis of …

Influence of doxycycline on clinical and angiographic outcome following percutaneous coronary intervention

M Kannengiesser, M Kaltenbach… - Journal of …, 2004 - Wiley Online Library
Background: Infection with Chlamydia pneumoniae may be involved in atherosclerosis.
Neointima proliferation after percutaneous coronary intervention (PCI) could be aggravated …

In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells

J Gieffers, W Solbach, M Maass - Cardiovascular drugs and therapy, 2001 - Springer
Recovery of viable Chlamydia pneumoniae from atheromas of coronary heart diseases
patients has initiated pilot studies to eradicate C. pneumoniae from vascular tissue by …